Agenus Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before November 5, 2024 to Discuss Your Rights – AGEN

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Agenus Inc. regarding a class action lawsuit due to allegations of misleading statements related to the effectiveness of their immuno-oncology products [1][2]. Group 1: Allegations and Class Period - The class period for the lawsuit is from January 23, 2023, to July 17, 2024 [2]. - Allegations include that the combination therapy of botensilimab and balstilimab was less effective than claimed, leading to overstated clinical results and regulatory prospects [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by the deadline of November 5, 2024, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4].